Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)

Conditions:   Gastric Cancer;   Gastroesophageal Junction Cancer Interventions:   Biological: Pembrolizumab;   Drug: Placebo;   Drug: Cisplatin;   Drug: Capecitabine;   Drug: 5-fluorouracil Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting - verified July 2017 (Source: ClinicalTrials.gov)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2toh9qt
via IFTTT